FDA rejects ecstasy as a therapy: what’s next for psychedelics?

FDA rejects MDMA (ecstasy) as a psychiatric treatment, prompting scientists to reassess how this decision could affect other psychedelic therapies in clinical trials. The story discusses Lykos Therapeutics’ plan to ask the FDA to reconsider and frames the broader consequences for hallucinogens being developed for psychiatric conditions. Attention shifts to which other substances may face similar regulatory scrutiny as clinical data and FDA standards shape the next steps for psychedelic medicine.